Is interleukin-6 an appropriate target to treat spondyloarthritis patients refractory to anti-tnf therapy? A cross-sectional national survey.
Résumé
ABSTRACT: INTRODUCTION: To evaluate the safety and efficacy of tocilizumab in patients having failed anti-TNFalpha therapy for spondyloarthritis, under real-life conditions. METHODS: French rheumatologists and internal-medicine practitioners registered on the Club Rhumatismes et Inflammations website were asked to report on patients given tocilizumab (4 or 8 mg/Kg) to treat active disease meeting ASAS criteria for axial or peripheral spondyloarthritis, after anti-TNFalpha treatment failure. Safety and efficacy after 3 and 6 months were assessed retrospectively using standardized questionnaires. RESULTS: Data were obtained for 21 patients, 13 with axial spondyloarthritis (46% men; median age, 42 years; disease duration, 11 years; HLA B27-positive, 92.3%) and 8 with peripheral spondyloarthritis (25% men; median age, 40 years; disease duration, 10 years; HLA B27-positive, 62.5%). No patients with axial disease had at least 20 mm decrease in BASDAI neither a BASDAI50 response or major ASDAS improvements after 3 or 6 months; an ASDAS clinically important improvement was noted at month-3 in 5 of 13 patients and at month-6 in 1 of 4 patients. A good DAS28 response was achieved in 4 patients with peripheral disease, including 1 in EULAR remission at month-3. At month-6, 4 patients were still taking tocilizumab including 1 in EULAR remission and 1 with a good DAS28 response. Tocilizumab was well tolerated, with no serious adverse events. Initially elevated acute-phase reactants declined during tocilizumab therapy. CONCLUSION: In patients having failed anti-TNFtherapy, tocilizumab decreased acute-phase reactants but failed to substantially improve axial spondyloarthritis and was inconsistently effective in peripheral spondyloarthritis.
Fichier principal
ar3766.pdf (170.41 Ko)
Télécharger le fichier
ar3766.xml (130.89 Ko)
Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Format : Autre
Loading...